Get the latest news on Alderon Iron Ore stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on AXXDF performance

Latest Alderon Iron Ore Stock News | OTC:AXXDF | Benzinga

Alderon Iron Ore Corp is a Canada based development-stage company. It is conducting iron ore evaluation activities related entirely to its Canadian properties located in western Labrador in the province of Newfoundland and Labrador. The company's operating segment is the acquisition, exploration, and evaluation of mineral resources. Its flagship project is the Kami Iron Ore project located in the Labrador Trough.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

ACRGF

AFOM

AITA

APPZ

ASDZF

BIEI

BTLLF

CBDS

CEIX

CHKDG

CHKDP

CLWD

CPPMF

CRGS

CSGH

CVVUF

DFIN

DLPN

DXBRF

ENDO

ETST

FCGD

FCSMF

FFNTF

FISOF

FIXX

GARB

GAXY

GGTTF

HCYT

HEWA

HEXO

HHBT

HNRG

HSDT

IDLM

IMAHF

JFIN

KERN

KHIRON LIFE SCIENCES CORP by Khiron Life Sciences Corp.

KHRNF

KOSK

KWBT

LUCRF

MADI

MCET

MMJFF

MRNJ

METALLIS RESOURCES INC by Metallis Resources, Inc.

MTLFF

MYGN

NCMI

NSPX

ORHOF

PLPL

PHOENIX LIFE SCIENCES INT by Phoenix Life Sciences International Ltd.

PLSI

PTEEF

RTIX

SBBP

SCIA

SNCR

SNDL

STIM

SWRM

TPT GLOBAL TECH INC by TPT Global Tech, Inc.

TPTW

TRVG

UBQU

VVCIF

RUPRF

TWIRF

AXXDF

DESTQ

AGRDF

NITMF

GLIIF

Stocks That Hit 52-Week Lows On Tuesday

AHPI

AKMNF

APCOF

ASDN

AXAS

BIOYF

BSQR

CBLI

CRWD

CURN

CWEGF

CYIG

DFFN

DOYU

EBRGF

ECDP

ENLC

EPEGQ

ESTR

FRHLF

FTSI

FTXP

GLAC

GLDFF

GNLN

GNPX

GTLS

GTY Technology Holdings, Inc. - Class A Ordinary Shares

GTYH

HITIF

IDFB

INND

INPX

IONKF

IPCIF

ISWH

ITKG

JROOF

KLDO

KENADYR MINING HLD CP ORD by Kenadyr Mining Holdings Corp

KNDYF

KNSA

LAIX

LDSR

LEMIF

LFCOF

LGF-A

LGF-B

LVRLF

MAYS

MINE

MOTS

MRMD

MTDR

MYMMF

NSTM

OPMZ

PGHEF

PPSI

PVBC

PWVI

RLLVF

RMNI

RIGHT ON BRANDS INC by Right On Brands, Inc.

RTON

RVSDF

RAVENQUEST BIOMED INC by Ravenquest Biomed Inc.

RVVQF

SBPH

SCPL

SFIV

SHLO

SLCA

SMTTF

SOLCF

SVIN

TCHC

TEUM

TMDI

TRXXF

TTNP

VIAB

VTLR

WTRH

SMTS

BFARF

LLEX

SCYYF

SWYDF

ENSV

Stocks That Hit 52-Week Lows On Thursday

ALDERON IRON ORE CORP by Alderon Iron Ore Corp.

Alderon Iron Ore Corp

Maxim Group analyst Anthony Vendetti initiates coverage on Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) with a Buy rating and announces Price Target of $6.

Price Target

Initiation

Analyst Ratings

SSKN

Maxim Group Initiates Coverage On Strata Skin Sciences with Buy Rating, Announces Price Target of $6

Maxim Group analyst Tate Sullivan initiates coverage on Stardust Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) with a Buy rating and announces Price Target of $1.75.

SDST

Maxim Group Initiates Coverage On Stardust Power with Buy Rating, Announces Price Target of $1.75

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has applied for a transportation charter-party carrier permit in California, signaling its intent to enter the ride-hailing market, Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-02-27/tesla-sets-sights-on-waymo-uber-in-california-ride-hailing-bid?srnd=homepage-americas&amp;sref=TBDibEcD">reports</a>. This move could provide a crucial new revenue stream as Tesla <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42777950/teslas-first-sales-drop-splits-wall-street-2025-will-be-the-prove-it-year">faces declining EV sales</a>, marking its first annual sales drop in over a decade. 
What To Know: While CEO Elon Musk has long envisioned a fully autonomous ride-hailing fleet, the application suggests Tesla will initially use human drivers, per Bloomberg. The permit Tesla is pursuing mirrors the one held by Waymo &#8211; Alphabet's robotaxi unit &#8211; but Tesla has yet to apply for a permit to operate fully autonomous vehicles in California.
Read Also: <a href="https://www.benzinga.com/general/market-summary/25/02/44018084/trumps-tariffs-potential-stagflation-whats-driving-markets-thursday">Trump&#8217;s Tariffs, Potential &#8216;Stagflation&#8217;: What&#8217;s Driving Markets Thursday?</a>
If approved, Tesla's entry into ride-hailing could directly challenge Uber, Lyft and Waymo. Musk has promised to <a href="https://www.benzinga.com/markets/equities/24/12/42575664/tesla-reportedly-in-talks-with-austin">launch the service in Austin by June</a> and expand to California by year-end, though specifics remain unclear. 
What Else: Tesla's push into ride-hailing aligns with Musk's broader focus on AI and robotics, particularly as regulatory and technological hurdles continue to delay full autonomy. 
Success in this space could help offset slowing car sales, but competition, regulatory challenges and the need for an effective ride-hailing infrastructure may complicate the rollout.
Read Next:<a href="https://www.benzinga.com/news/econ-s/25/02/43977811/mortgage-rates-drop-to-lowest-levels-since-december-but-housing-market-remains-largely-stuck" target="_blank" rel="noreferrer noopener"></a>
<ul>
<li><a href="https://www.benzinga.com/news/econ-s/25/02/43977811/mortgage-rates-drop-to-lowest-levels-since-december-but-housing-market-remains-largely-stuck" target="_blank" rel="noreferrer noopener">Mortgage Rates Drop To Lowest Levels Since December, But Housing Market Remains ‘Largely Stuck' </a></li>
</ul>
Photo: Shutterstock

TSLA

Tesla Seeks California Ride-Hailing Permit Amid Declining EV Sales

Citigroup analyst Ronald Josey downgrades Ibotta (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NYSE">IBTA</a>) from Buy to Neutral and lowers the price target from $82 to $44.

Downgrades

IBTA

Citigroup Downgrades Ibotta to Neutral, Lowers Price Target to $44

Citigroup analyst Jon Tower maintains Sweetgreen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) with a Buy and lowers the price target from $43 to $39.

Citigroup Maintains Buy on Sweetgreen, Lowers Price Target to $39

On Thursday, NovoCure Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) reported a fourth-quarter loss of 61 cents, down from the 45-cent loss reported a year ago, missing the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss of 34 cents</a>.
Sales increased 21% year over year to $161.27 million, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b44002398/novocure-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-company-update" rel="noreferrer noopener">consensus of $157.81 million</a>.
<ul>
<li>The U.S., Germany, France and Japan contributed $107.2 million, $17.4 million, $15.7 million and $8.5 million in quarterly net revenues, respectively, with other active markets contributing $10.4 million.</li>
<li>Revenue in Greater China from Novocure's partnership with Zai Lab totaled $2.0 million.</li>
<li>Improved approval rates in the U.S. resulted in $8.3 million of increased net revenue from prior period claims during the quarter.</li>
</ul>
Annual sales reached $605 million, an increase of 19% year-over-year, primarily driven by continued launch success in France for Optune Gio, a wearable, portable, FDA-approved device indicated to treat a type of brain cancer in adult patients 22 years of age or older. Gross margin for the quarter was 79%.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42268730/novocures-recently-approved-tumor-treating-electric-fields-shows-promise-in-pancreatic-cancer-patients" rel="noreferrer noopener">NovoCure&#8217;s Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients</a>
As of December 31, 2024, there were 4,126 total active patients on TTFields therapy globally, with 4,077 active Optune Gio patients on therapy.
As of December 31, 2024, 20 active metastatic NSCLC patients and 29 active malignant pleural mesothelioma (MPM) patients were on Optune Lua, a wearable, portable, FDA-approved device used together with PD-1/PD-L1 inhibitors (immunotherapy) or docetaxel for adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41353867/fda-approves-novocures-portable-device-producing-tumor-treating-electric-fields-for-previously-tr" rel="noreferrer noopener">or after a platinum-based regimen</a>.
In 2025, Novocure expects gross margins will be impacted by current and future product enhancements, such as the U.S. launch of Head Flexible Electrode (HFE) transducer arrays for use with Optune Gio and the launch of Optune Lua in mNSCLC.
Net revenue growth in 2025 is expected to reflect growth in Optune Gio active patients. As the GBM business reaches maturity, the company expects to continue growing at a low, mid-single-digit rate this year.
Price Action: NVCR stock is down 10% at $19.77 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/44011524/dentsply-sirona-q4-earnings-miss-10-sales-drop-soft-2025-outlook-and-more" target="_blank" rel="noreferrer noopener">Dentsply Sirona Q4: Earnings Miss, 10% Sales Drop, Soft 2025 Outlook And More</a></li>
</ul>
Photo via Shutterstock.

Biotech

NovoCure Reports Wider Than Expected Q4 Loss Despite 21% Jump In Sales, Expects Product Enhancements To Hit Gross Margin In 2025

Comments

Alderon Iron Ore Stock News

News

Latest Alderon Iron Ore Stock News | OTC:AXXDF | Benzinga

Tuesday, November 05, 2019

Thursday, October 17, 2019

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga